"rationale","instanceType","name","description","id","uuid:ID","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","Study Design 1","The main design for the study","StudyDesign_1","3d042462-900f-425c-bbde-f3f1df7cb319",""
